Nuveen LLC Takes Position in ASP Isotopes Inc. $ASPI

Key Points

• Nuveen LLC has acquired a new stake of 131,230 shares in ASP Isotopes Inc., valued at approximately $615,000, representing about 0.17% of the company's stock.
• ASP Isotopes recently faced challenges, reporting a quarterly loss of ($1.03) EPS, which was significantly below market expectations.
• Analysts have given ASP Isotopes a "buy" rating while Canaccord Genuity raised the price target from $8.50 to $11.00.

Nuveen LLC purchased a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 131,230 shares of the company's stock, valued at approximately $615,000. Nuveen LLC owned about 0.17% of ASP Isotopes at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in ASP Isotopes in the fourth quarter valued at approximately $34,000. SBI Securities Co. Ltd. raised its stake in ASP Isotopes by 84.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after acquiring an additional 4,299 shares in the last quarter. Millennium Management LLC acquired a new position in shares of ASP Isotopes in the 4th quarter worth $55,000. Fortitude Advisory Group L.L.C. bought a new stake in shares of ASP Isotopes during the 1st quarter worth about $64,000. Finally, ProShare Advisors LLC acquired a new position in shares of ASP Isotopes in the 4th quarter valued at $67,000. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group increased their price target on ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, ASP Isotopes has an average rating of "Buy" and a consensus price target of $7.75.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, Director Duncan Moore sold 75,000 shares of the business's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $9.28, for a total transaction of $696,000.00. Following the sale, the director directly owned 994,553 shares in the company, valued at approximately $9,229,451.84. The trade was a 7.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 21.40% of the company's stock.

ASP Isotopes Price Performance

Shares of NASDAQ:ASPI traded up $0.45 during mid-day trading on Monday, reaching $8.66. The stock had a trading volume of 2,582,033 shares, compared to its average volume of 3,219,606. The company has a market cap of $795.48 million, a P/E ratio of -14.18 and a beta of 3.36. The business's 50 day moving average price is $9.00 and its 200 day moving average price is $7.04. ASP Isotopes Inc. has a 1 year low of $2.12 and a 1 year high of $11.68. The company has a current ratio of 14.72, a quick ratio of 14.56 and a debt-to-equity ratio of 3.53.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.92). The firm had revenue of $1.20 million during the quarter, compared to analyst estimates of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. Research analysts expect that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.